Emerging Therapies and Future Outlook for Patients with EGFR-Mutant NSCLC

Panelists discuss how the next generation of targeted agents, including sunvozertinib, BLU-945, and antibody-drug conjugates, promises to further refine the treatment paradigm. These emerging therapies aim to address resistance mutations and improve efficacy in patients who have exhausted current options.

They foresee a near future where treatment decisions will increasingly rely on dynamic molecular profiling, enabling real-time adjustment of therapeutic strategies. The integration of novel agents into sequencing frameworks will likely expand patient longevity and quality of life.

Panelists express optimism that the evolving pipeline will transform EGFR-mutant non–small-cell lung cancer (NSCLC) from a once rapidly fatal disease into a chronically managed condition. Collaboration between clinical research and practice remains key to realizing this vision.